The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2017 | Combining radiotherapy and the immune system in lymphomas
Timothy Illidge, BSc, PhD, MRCP, FRCR, FRCPath, from University of Manchester, Manchester, UK, provides an overview of his talk on immunomodulatory treatment and radiation therapy in lymphomas at the International Conference on Malignant Lymphoma (ICML) 2017 in Lugano, Switzerland. The basis of his work rests on the hypothesis that radiotherapy induces immunogenic tumour cell death. His findings show how radiotherapy in low doses can bring about an adaptive immune response, whereby tumour cells begin expressing PD-L1, which can then be targeted by anti-PD-1/PD-L1 inhibitors. This can lead to long term tumour control. Translating this into clinical trials is the next step. This video has been supported by Napp Pharmaceuticals Ltd through an unrestricted educational grant to Magdalen Medical Publishing.
